Embecta Corp. (NASDAQ: EMBC)

This lawsuit is for anyone who acquired securities in Embecta Corp. (NASDAQ: EMBC) from November 25, 2025 through May 4, 2026.

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit alleges that, throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by repeatedly reassuring investors that its pen needle segment remained resilient and stable despite competitive pressures and changes in the diabetes treatment market, while repeatedly reaffirming revenue and earnings guidance despite knowing that weakening demand, competitive share losses, and adverse market trends in its U.S. pen needle business were likely to cause the Company to miss expectations and significantly reduce its financial outlook.

On May 5, 2026, Embecta released its second quarter fiscal 2026 financial results, revealing that revenue had declined over 14%, largely due to weakness in its pen needle sales. Additionally, the Company lowered its guidance for the remainder of fiscal 2026. On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Embecta Corp. (NASDAQ: EMBC) from November 25, 2025 through May 4, 2026 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.